Key result
Beta-blockers are indicated for all myocardial infarction survivors without absolute contraindications, while digoxin, verapamil, and diltiazem are reserved for specific clinical scenarios.
This review summarizes the indications for heart-rate slowing drugs in the secondary prevention of myocardial infarction.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vítovec et al. (2009) conducted a review in Myocardial infarction. Heart-rate slowing drugs (beta-blockers, digoxin, verapamil, diltiazem, ivabradine) was evaluated. Beta-blockers are indicated for all myocardial infarction survivors without absolute contraindications, while digoxin, verapamil, and diltiazem are reserved for specific clinical scenarios.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: